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[57] ABSTRACT 
3-Thia-7-azabicyclo(3.3.1 )nonanes and derivatives 
thereof are disclosed. The preparation of these com-
pounds is given. Their use as antiarrhythmic agents is 
given. 




DERIVATIVES AS ANTIARRHYTHMIC AGENTS 
BACKGROUND OF THE INVENTION 5 
l. Field of the Invention 
This invention relates to antiarrhythmic composi-
tions. More specifically, the invention relates to certain 
3-thia-7-azabicyclo[3.3. l]nonanes and derivatives 10 
thereof. 
2. Description of the Prior Art 
3-azabicyclo[3.3. l]nonanes, including bicyclic sys-
tems with one heteroatom such as N, S and O and vari-
ous derivatives, are known and are documented in the 15 
chemical literature. In a recent Chemical Reviews arti-
cle, 1981, Vol. 81, No. 2, pages 149-174, entitled 
"Chemistry of 3-Azabicyclo[3.3.l]nonanes" by R. 
Jeyaraman and S. Avila the synthesis, stereochemistry, 20 
and reactions of such compounds are reviewed. This 
article acknowledges the close resemblance of aza- and 
diazaadamantanes in conformation and stereochemistry 
to the 3-azabicyclo[3.3. l]nonanes as a cause for signifi-
cant progress in the azabicyclononane (ABN) studies. 25 
The article further acknowledges the ease of formation 
of 3-ABNs from simple ketones and aldehydes through 
the Mannich reaction without the involvement of com-
plicated reaction conditions and reagents and the ready 
availability of a reactive carbonyl group in most of the 30 
ABNs prepared as important reasons for widespread 
studies on ABNs. 
According to the existing chemical literature, some 
derivatives of 3-ABN have been found to possess useful 35 
biological activities. The observed biological activities 
have included potent analgesic properties and antitusive 
activities as well as antagonism to analgesic effects and 
even weak narcotic antagonism depending on the par-
ticular compound involved. Some have displayed local 40 
anesthetic activity and simple 3-ABN is reportedly ef-
fective against influenza infection. Other derivatives of 
3-ABN have displayed powerful ganglioplegic and 
hypotensive properties. Several have been found to be 
sedatives, antipyretics, and psycholaleptic and hypogly- 45 
cemic agents. Some 3,7-diazabicyclo[3.3.l]nonanes pos-
sess antiarrhythmic potencies. 
The Chemical Reviews article further described the 
subclass of 3-thia-7-azabicyclo[3.3. l]nonanes as being of 
much less interest and identifies a series of diphenyl 50 
and/or diary} substituted derivatives as having been 
prepared through the Mannich reaction. 
SUMMARY OF THE INVENTION 
h . . . l I 3 hi 
55 
T e present mvent1on mvo ves nove -t a-7-
azabicyclo[3.3. l]nonanes compositions selected from 
the group consisting of: 
(a) 




-CH,-©-X ~ -CH,-CH,-©-X 
• 
and X is either H, Cl or OCH3; 
(b) 
where R is 
and X is either H, Cl or OCH3 and Y is Cl, Br or ClO4; 
(c) 
where R is 
and X is either H, Cl or OCH3; 
(d) 
where R is 
and X is either H, Cl or OCH3 and Y is Cl, Br or CIO4; 
(e) 




and X is either H, Cl, or OCH3 and Ar is 
and 
(f) 
where R is 
'and X is either H, Cl or OCH3 and Ar is 
and Y is Cl, Br or ClO4. 
4 
droxylated carbon. The compounds with a carbonyl 
group at the 9-position will be referred to as bispidones 
and the others as bispidines. 
These compounds are potential drugs for use in the 
5 treatment of disorders of the heart. They display good 
antiarrhythmic activity and as such are viable candi-
dates to control arrhythmias in humans who have suf-
fered major heart attacks or infarctions. 
Typically, the ketones (e.g. bispidones) are synthe-
10 sized by the reaction of tetrahydrothiopyranone with 
formaldehyde and benzylamine according to the Man-
nich reaction as follows: 
15 
20 The corresponding bispidines and respective deriva-
tives of either the bispidines and bispidones can be 
readily synthesized by making the appropriate selection 
of reactants for the Mannich reaction and/or by selec-
tive oxidation or reduction at the 9-position as exempli-
25 tied later. The Mannich reaction is particularly useful in 
that, as previously indicated, it does not require compli-
cated reaction conditions and reagents. However for 
purposes of the present invention, other methods of 
synthesis well known in the art should be considered 
30 equivalent. For example and for more detailed disclo-
sure of various alternative methods of synthesis (includ-
ing the Mannich reaction) and methods of synthesis of 
various subsequent derivatives, the previously men-
tioned Chemical Reviews article by Jeyaraman et al is 
35 again cited and herein incorporated by reference for 
such purposes. Furthermore, according to the preferred 
embodiments of the present invention, the water solu-
bility of the 3-thia-7-azabicyclo[3.3.l]nonane com-
More specifically, the invention relates to 7-benzyl-3- 40 
thia-7-azabicyclo[3.3. l)nonane, its hydrogen perchlo-
rate amine salt and the corresponding 9-hydroxyl-9-
phenyl or 9-one derivatives. The present invention fur-
ther provides for the use of the above compositions in 
pounds can be advantageously enhanced by formation 
of corresponding tertiary amines salts and the like prior 
to patient treatment. 
In order to further illustrate the formation of the 
3-thia-7-azabicyclo[3.3. l]nonane according to the pres-
ent invention, the preparation and isolation of a puri-
fied, water soluble, biologically-active tertiary amine 
salt thereof and the antiarryhythmic activity of the 
an antiarrhythmic process. 45 
Thus, it is an object of the present invention to pro-
vide novel compositions that display biological activity. 
Fulfillment of this object and the presence and fulfill-
ment of other objects will be apparent upon complete 
compositions, the following sequence of examples are 
presented. 
reading of the specification and claims. 50 EXAMPLE I 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The chemical compositions according to the pre-
ferred embodiments of the present invention are 
heteronuclear ring organic compounds based on the 
3-azabicyclo[3.3.l)nonane structure as follows: 
2 1 8 
'S~N-R-• 
4 5 6 
Preparation of 
7-Benzyl-3-thia-7-azabicyclo[3.3. l)nonan-9-one 
A solution containing 0.46 g (4.3 mmol) of benzyl-
55 amine and 1.0 g (33.0 mmol) ofparaformaldehyde in 15 
ml of methyl alcohol was made acidic with acetic acid 
(0.38 g). To this solution was added 0.5 g (4.3 mmol) or 
4-thianone (tetrahydrothiopyranone), and the resulting 
solution was heated to reflux for 5-6 hours. Evapora-
60 tion of the solvent on a rotary evaporator gave a heavy 
red oil which was partitioned between 30 ml of water 
and 30 ml of diethyl ether. The organic layer was dis-
carded and the aqueous layer was made strongly basic 
wherein the 3 position is a sulfur atom (thia) and the 65 
7-position is an alkylated nitrogen atom (aryl substituted 
tertiary amine). The 9-position can either be an unsub-
stituted carbon, a carbonyl group or an arylated, hy-
with 0.3 g (7.5 mmol) of sodium hydroxide pellets. The 
resulting solution was extracted with diethyl ether (four 
30 ml portions), and the extracts were combined and 
dried over Na2SO4. The dried solution (yellow) was 
filtered and evaporated on a rotary evaporator to give a 
5 
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brownish-yellow oil which soiidified upon standing. 
Treatment of the solid with 100 ml of a petroleum ether 
sold under the tradename Skelly B (boiling point 
60°-68° C.) on a steam bath for 30 minutes gave a solu-
tion which was filtered hot. Evaporation of the solvent 5 
produced 0.5 g of a light yellow solid. Sublimation 
(80° /0.025 mm) of this solid gave 0.4 g (38%) of the title 
compound melting at 91°-92° C. 
Analytical confirmation of the structural formula: 
10 
S C=O N-CH2 
6 
60%, same as above). Small white crystals separated 
and were filtered off and washed with fresh diethyl 
ether (50 ml). These crystals were dried for 20 minutes 
at room temperature/20 mm; the yield was 0.55 g 
(83%), m.p. 155°-156° c. 
Analytical confirmation of the structural formula: 
CH2-CH-CH2 -© 
/ ' ' S CH2 +N-CH2 0 ; CI04-' / /' CH2-CH-CH2 H 
was as follows. Elemental analysis found 49.99% C; 
CH2-CH-CH2 .-© / ' ' 0 ' / / 
CH2-CH-CH2 
15 6.07% H; 4.13% N; and 9.68% S (by weight) which 
was as follows. Elemental analysis found 68.01 % C; corresponds to the empirical formula C14-ff20ClN04S 
6.96% H; 5.67% N and 13.07% s (by weight) which (50.37 C, 6.99 H, 4.19 N and 9.60%S). Mass spectrome-
corresponds to the empirical formula Ct4-fft7Nos ter peak matching of the molecular ion gave a mass to 
(68.02 C, 6.88 H, 5.67 N and 12.95%S). Mass spectrome- charge ratio of 233.12~8 compared to theoretical m/e of 
ter peak matching of the molecular ion gave a mass to 20 233.123~. An ~bsorption peak at 3400 cm_- 1 was ob-
charge ratio of 247.1031 exactly corresponding to the serve~ m the mfrared spectra (KBr !echnique) corre-
theotetical ml e ratio. An absorption peak at 1720 cm -1 spondmg to the presence of the nitrogen-hydrogen 
was observed in the infrared spectra (KBr technique) bond of the amine salt. Again, both hydrogen and car-
corresponding to the presence of a carbonyl group. bon-13 NMR data was measured on a Varian XL(lOO) 
Both hydrogen and carbon-13 NMR spectral shifts 25 spectrometer using tetramethylsilane as the standard. 
were measured from the tetramethylsilane standard on a The NMR results were as follows: 
Varian XL(lOO) spectrometer confirming the correct 1H NMR (DMSO-d6) 6 1.6-3.1 [m, 12 H, ring H], 
hydrogen distribution and carbon atom spectral assign- 4.27 [s, 2 H, CH2-C6Hs], 7.5 [m, 5 H, Ar-H], 9.25 [s, 1 H, 
ments as follows: NH] and 13CNMR [This data is for tiie free amine 
1H NMR (DCCh) 6 2.25-3.25 [m, 10 H, ring H], 3.5 30 rather than for the perchlorate] (DCCh) ppm; C(l,5), 
[s, 2 H, CH2Ar], 7.25 [m, 5 H, Ar-!:!]and 13C NMR 27.14; C(2,4) 31.49; C(6,8), 58.54; C(9) 29.76; C6HsCH2 
(DCCIJ) ppm: C(l,5) 47.06; C(2,4) 34.67; C(6,8) 58.30; 63.18; C(Ar-C) 126.35, 127.84, 128.37, 138.96. -
C(9) 212.84; C6HsCH2 61.30; C(Ar-9 C(a) 137.93; C(/3) 







clo[3.3. l]nonane Hydrogen Perchlorate 
7-Benzyl-3-thia-7-azabicyclo[3.3. l]nonane Hydrogen 
Perchlorate A solution of0.95 g (6.1 mmol) ofbromobenzene in 
. . . 40 40 ml of dry diethyl ether was slowly added over a To. a solut10n of 10 ml of tneth~lene glycol which period of one hour to 0.2 g (8.3 g. at.) of magnesium in 
contained 2 g (62.5 mmol) ofhydrazme was added 0.5 g db fl k · · h · · 
(2.0 mmol) of 7_benz 1_3_thia-7- b' 1 [3 3 l] _ a r?un . ottom as eqwpped ~It a magnetic stirrer. Y . aza icyc O • • nonan This mixture was allowed to stir for one hour under 
9-one prepared accordmg to the process of Example I. •t Th G · d t fi d th 
When the addition was complete, 3.5 g of potassium m rogen. . e ngnar reagen orme was . en 
hydroxide pellets were added, and the resulting mixture 45 treat~d with o.5 g (2,0 mmol)_ of 7-be~yl-3-t~a-7-
was heated to 145• -150• c. under nitrogen for 4 hours. azabicyclo[3.3. l]non~-?-one which was dissolved m 25 
During this time, 1.5 ml of distillate was removed by the m! ~f ether. Th~ add1t10n was performed slowly and 
use of a fractional distillation take-off unit. After 4 stirrmg wa~ co_ntmued for one hour. 
hours, the solution which resulted was cooled to room After this time, 20_ ml ~f 9M H2SO~ was added 
temperature and then diluted with water (30 ml). This 50 slowly, and the resulting mixture was stirred for one 
new solution was extracted with diethyl ether (three h?ur. Two layers sep_arated and th~ ether l~yer ~as 
30-ml portions). The ether extracts were combined and discarded. After coohng the organic layer m an ice 
drived over MgSO4. After the dried ether extracts were bat~, th_e layer was !11ade b~ic with KOH pellets. This 
filtered, the resulting solution was cooled to o• c. and 2 basic mixture was diluted with 100 ml of water and was 
ml of perchloric acid (60% solution-Mallinckrodt, ana- 55 then extrac~ed with 3-~0 ml portions of ether which 
lytical Reagent) was slowly added. Small white needle- were combmed and dned (KOH). The ether solution 
like crystals separated and were filtered and washed was decanted into a dry beaker. To this solution was 
with fresh diethyl ether (50 ml). Recrystallization of the added dropwise a solution of perchloric acid (60% in 
crystals was effected with 95% ethyl alcohol. The solid water) with stirring until no additional white percipitate 
which resulted was placed in water (50 ml, room tern- 60 formed. The white solid observed was filtered and 
perature) which contained 1.0 g of potassium hydroxide washed with 20 ml of fresh ether. Recrystallization 
pellets. A suspension resulted which slowly became a (95% ethanol) of the white solid gave 0.69 g (81 % ) of 
solution upon stirring (5 minutes). Extraction of this the title alcohol, melting at 249°-250° C. 
solution followed with diethyl ether (three 30-ml por- Analytical confirmation of the structure was as fol-
tions), and the extracts were combined and dried over 65 lows. Elemental analysis found 56.45% C; 5.70% H; 
MgSO4. Filtering removed the drying agent, and the 3.27% N; 7.65% S; and 8.70% Cl (by weight) which 
resulting solution was cooled to o• C. To this solution corresponds to the empirical formula C20H2~OsSCl 




absorption peak occurred at 3490 cm - 1 in the infrared 
spectrum of the title compound. 
Since the salt was not soluble in all of the common 
solvents examined and often used for NMR analysis, the 
material was converted to the free amine. The salt was 5 
placed in water and the solution was made basic 
(NaOH). Extraction of this solution was achieved with 
3 50-ml portions of diethyl ether. The extracts were 
combined and dried (Na2SO4). Evaporation of the ether 
gave the solid aminoalcohol, 9-hydroxyl-9-phenyl-7- 10 
benzyl-3-thia-7-azabicyclo[3.3.1Jnonane which melted 
electrical activity (during the tachycardia), usually 
from the epicardial area overlying the infarct, suggests 
a reentrant rather than an automatic mechanism for this 
arrhythmia. 
Four dogs were studied with the 3-thia-7-ABN com-
position of Example II. In the control state, two types of 
arrhythmias were seen. There were spontaneous and 
intermittent accelerated idoventricular rhythms whose 
rate averaged 164/min. Also, sustained rapid ventricu-
lar tachycardias could be induced by ventricular paced 
beats. These tachycardias, which were consistently 
monomorphic (QRS complex), averaged 340/min. The 
compound caused little or no change in the spontaneous 
arrhythmias (which were due to an automatic mecha-
at 112°-113° C. NMR spectral data on this free amine 
are as follows. 1H NMR (DCCl3) 6 2.2[s, 1 H, OH), 
2.4-3.0 [m, 8 HJ, 3.65-3.75 [dd, 2 HJ, 3.3 [s, 2 H, Ar-
CH2J, and 7.15-7.4 [m, 10 H, Ar-!!). 
EXAMPLE IV 
15 nism), but markedly slowed the induced tachycardia 
(due to a reentrant mechanism) by as much as 100 
beats/min. In some cases after addition of the drug, the 
Using four dogs and three dosage rates (i.e., 6, 12 and tachycardias were either not inducible or self-terminat-
18 mg/kg; i.e., mg of compound per kg of body weight ing. The peak effects occurred at doses of 6-12 mg/kg. 
of dog) of the hydrogen perchlorate salt prepared ac- 20 No further response was noted at 18 mg/kg. The dura-
cording to Example II dissolved in 50% ethanol, the tion of action was 20-40 minutes. In one case, before 
following techniques were employed and respective addition of the drug, ventricular fibrillation was in-
results were obtained. duced rather than created via ventricular tachycardia 
In the anesthetized dog (30 mg/kg-sodium pentobar- by ventricular pacing. This induction occurred at the 
bital administered intravenously), the left anterior de- 25 low rate of 240 beats/min. Indeed the compound caused 
scending coronary artery was ligated and the animal the induction of ventricular fibrillation as a result of 
allowed to recover for 24 hours. Under anesthesia and ventricular pacing but at the rate of 360-390/min. Forty 
controlled ventilation, a 12-lead electrocardiogram was minutes after the drug effect had subsided, the ventricu-
taken to establish the presence oftransmural myocardial lar fibrillation was again induced at a rate of 240/min . 
... infarction. At this time ventricular escape beats and 30 Insofar as the effect of the compound on conduction, 
multifocal accelelerated idioventricular rhythms were there was little or no effect on intraatrial, His-Purinkje 
commonly seen interspersed with the sinus rhythm. and ventricular muscle conduction. A-V nodal conduc-
The original left-lateral thoracotomy was reopened tion was slightly enhanced at all doses. 
and the following electrical recordings were made: In addition, the compound causes a 10-15% increase 
standard leads II of the electrocardiogram; His bundle 35 in mean blood pressure during sinus rhythm and during 
electrogram via a catheter in the left ventricle in contact sustained ventricular tachycardia. In the control states, 
-with the infarcted endocardium bordering the infarct; blood pressure was so low during sustained ventricular 
-an electrode catheter in the right ventricle in contact tachycardia (=20 mmHg) that cardioversion or electri-
·with non-infarcted endocardium; a special composite cal pacing had to be used to terminate the arrhythmia. 
electrode on the left ventricular epicardial surface over- 40 Such termination prevented degeneration of the sus-
lying the infarct; another composite electrode on the tained ventricular tachycardia into ventricular fibrilla-
non-infarcted posterior epicardium of the left ventricle. tion. After the addition of the drug, mean arterial blood 
Mean arterial blood pressure was monitored continu- pressure was 50-60% higher, and, moreover, the tachy-
ously. Two silver wires were inserted into the left vago- cardia was slower. Therefore, the arrhythmia was easily 
sympathetic trunk. By delivering high frequency (20 45 tolerated for long periods without degeneration into 
Hz) square wave pulses to the nerve trunk, the heart ventricular fibrillation. No change in the effects of 
rate could be slowed sufficiently to expose the underly- vagal stimulation were seen with this agent, that is, the 
ing ventricular rhythm. In this way the ventricular degree of sinus inhibition and/or A-V block were simi-
automaticity could be unmasked without interference of Jar before and after the drug. 
a competing sinus pacemaker. Other pairs of wires were 50 Thus use of 7-benzyl-3-thia-7-azabicyclo[3.3. lJno-
inserted into the right artium for artrial pacing and thfe nane hydrogen perchlorate and related compounds is 
right ventricle for ventricular pacing. viewed as promising in that induced ventricular tachy-
Vagal stimulation was applied to determine the un- cardias, which are life-threatening can be markedly 
derlying ventricular automatically, which, in these slowed and most important, blood pressure, instead of 
preparations, averaged=164/min. Atrial pacing at rates 55 being depressed, is actually increased so that the malig-
from 180/min up to the rate at which second degree nant character of the ventricular arrhythmia, i.e., pro-
A-V block was induced (=300/min) was performed duction of symptoms, is dramatically removed. In the 
before and after drug administration in order to deter- context of use of such an agent, the goal of therapy 
mine the effects of the compound upon intraatrial, A-V would be to abolish symptoms, i.e., lightheadness, syn-
nodal, His-Purkinje, and ventricular muscle conduc- 60 cope, and in this way prevent sudden death. Thus, the 
tion. Ventricular pacing was then instituted by ran- use of high doses of depressant substances would not be 
domly introducing three ventricular paced beats at rates necessary to prevent absolute inducibility of ventricular 
from 240 to 420/min. It was found that this method arrhythmias and their commonly associated fatal conse-
results in the induction of rapid sustained ventricular quences. 
tachycardia (averaging 350/min). If rapid pacing or 65 Fifty percent ethanol solution was injected into the 
cardioversion is not instituted within one to two min- dogs in order to determine if some or any of the effects 
utes, these tachycardias degenerate into ventricular of the drug were due to the solvent. Ethanol injected 




but transient decrease in arterial blood pressure and no cording was diminished in amplitude and displayed a 
appreciable changes into ventricular ectopic activity 2: 1 pattern with a fractionated potential in one beat 
either of the automatic · or the reentrant type. There alternating with one component in the next beat. This is 
were no other remarkable responses to ethanol injec- associated with a suppression of the ventricular ectopic 
tions. 5 beats since the fractionated potential in every other beat 
Since recent• reports have indicated that calcium did not extend beyond the T wave to induce a reentrant 
blockers, such as verapamil and nifedipine, have antiar- ectopic beat. However, in the third beat a ventricular 
rhythmic properties, several experiments were per- ectopic beat manifested as a fusion beat F (there was 
formed to examine the comparative calcium blocking observed a short P-R interval and aberrant QRS com-
properties. Comparison of the effects of the composi- 10 plex). This is associated with a fractionated potential, 
tion of Example II versus those of verapamil or D-600 well beyond the previous T wave allowing a reentrant 
drugs on the electrophysiology and hemodynamics of activation to occur. Mean blood pressure was slightly 
the 24-hour infarcted dog heart is summarized in the depressed by lidocaine and was in the range 103-95 mm 
following table of results: Hg. 
_________ T_A_B_L_E ________ 15 With a higher dose oflidocaine (6 mg/kg), there was 
observed a further depression of the electrogram ampli-
tude (IZ eg) and the 2: 1 pattern of the morphology of 

























Thus, the above evidence suggests that compositions of 
2 
was complete suppression of the ventricular ectopic 
0 beats and the mean blood pressure stabilized at 95 mm 
Hg. 
After a period of twenty minutes, the effect of the 
larger dose of lidocaine had dissipated. There was ob-
25 served a return of the electrogram pattern of Wencke-
bach which is normally associated with a ventricular 
ectopic beat (VPB) after two sinus beats. The mean 
blood pressure returned to control levels, namely 106 
.. .the present invention have several actions which are 
diametrically opposite to those of known calcium 30 
blocking agents and that 7-benzyl-3-thia-7-ABN hydro-
gen perchlorate does not appear to be a calcium 
blocker. 
mm Hg . 
A dose of the composition of EXAMPLE II (3 
mg/kg) was given intravenously in a solution of 1:1 
water:ethanol with a total volume of 3.3 ml. Within one 
minute, the blood pressure rose from 106 to 138 mm 
HG. At the same time there was observed a marked 
EXAMPLEV 
35 depression of the amplitude of the IZ eg potentials and 
Studies on the Comparison of Examples I, II and III in a 2:1 alternation of the configuration of the recorded 
Subacute Stages of Myocardial Infarctions in Dogs deflections. Moreover, there was a sharp fractionation 
, . The studies which are outlined use the compositions of the IZ eg potentials indicating that EXAMPLE II 
, .. , produced in EXAMPLES I, II and. III as well as the markedly slowed the conduction in the abnormal tissue . 
. ,. clinically-used drug lidocaine for comparison purposes 40 Potentials in the other areas observed were relatively 
:t:· · in the treatment of induced ventricular tachycardias of unaffected. In contrast to the action of lidocaine at the 
infarcted dog heart 4 days after the left anterior artery same dose level, EXAMPLE II showed a more potent 
occlusion. Electrodes were positioned on the heart for antiarrhythmic effect related to its selective depression 
examination of the electrogram behavior in areas of of the conduction in the reentrant pathway depressed 
slow conduction which are critical to the initiation and 45 tissue). Quite significant was the observation that rather 
maintenance of arrhythmias. For this purpose, the 4-day than depressing blood pressure, EXAMPLE II caused a 
infarcted heart was pretreated with methylpredniso- substantial presser effect (28%). 
lone. The first electrical recordings were made from an After a period of 40 minutes, the effect of EXAM-
infarcted dog heart 4 days after the left anterior coro- PLE II had ceased as evidenced by a return of the· 
nary artery was occluded. It was observed that the area 50 electrical and hemodynamic properties to the control 
over the infarct was viable but sick since the electro- state. Addition of the composition of EXAMPLE I (3 
gram displayed a low amplitude and was intermittently mg/kg) caused a smaller change in electrical properties 
fractionated. The first four beats showed a 2:1 pattern of compared to that observed with EXAMPLE II. The 
fractionation in the (IZ eg) recording. The next three amplitude of the potentials recorded from the IZ eg 
beats showed a progressive delay ofthe fractionation in 55 were not as diminished, and, although the 2:1 pattern of 
a Wenckebach fashion until a portion of the fraction- block was produced in relation to the fractioned poten-
ated potential occurred after the T wave of the previous tial, the deflection showed progressive fragmentation 
sinus beat. This is coincident with the occurrence of a and delay which occasionally manifested as a ventricu-
premature ventricular beat (VPB). The sequence of lar ectopic beat (VPB). In this beat, the delayed poten-
events suggested a reentrant mechanism whereby con- 60 tial occurred after the end of the T wave of the previous 
duction delay of the impulse in the infarcted zone was sinus beat. Mean blood pressure was elevated from 108 
sustained, compared to the refractoriness of the rest of to 124 mm Hg. 
the heart, and reentered the normal tissues causing an Again after the effect of EXAMPLE I had ceased, a 
ectopic beat. The mean blood pressure recorded during solution of the composition of EXAMPLE III was 
this sequence was 103 mm Hg. 65 injected (3 mg/kg). The effects of the marked depres-
When lidocaine (3 mg/kg), the standard antiarrhyth- sion of the IZ eg electrograms and the disappearance of 
mic agent, was used, a dramatic effect on the reentrant the arrhythmias appeared similar to those observed 
arrhythmia was observed as expected. The IZ eg re- with EXAMPLE II. There was also a widening of the 
11 
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QRS duration (from 45-75 msec) and H-V interval 
(from 32-45 msec). Also, the endocardial electrogram 
was diminished slightly and delay occurred between the 
Purkinje potential (p) and muscle potential (M). Thus, it 
appears that this EXAMPLE III is less sensitive in 5 
terms of its negative dromotropic action since both 
normal and abnormal tissues are affected. In a few cases 
with EXAMPLE II at high doses (18 mg/kg), a similar 
widening of the QRS complex was noted and caused 
ventricular ectopic bears. Mean blood pressure with 10 
EXAMPLE III was still elevated (from 108 to 120 mm 
Hg). 
In summary, there is good evidence that EXAMPLE 
II has a more potent effect on arrhythmias due to con-
duction defects in ischemically damaged hearts than 15 
does the clinically-used lidocaine at similar doses. In 
addition, a positive pressor response is associated with 
EXAMPLE II but not with lidocaine. The relative, 
namely EXAMPLE I, had less effect on the abnormal 
conduction but did show a positive blood pressure ef- 20 
feet. EXAMPLE III raised blood pressure slightly but 
also had a potent depressant effect on normal and ab-
normal areas of conduction. Consequently, there ap-
pears to be a profile of useful activity in this particular 
family of heterocycles. 25 
In principle, it is felt that the compositions of the 
present invention can be employed by themselves, in 
combination with each other, or in combination with 
· other drugs to achieve either individually or in combi-
nation the desired antiarrhythmic properties. It is envi- 30 
sioned that the composition can be utilized and adminis-
tered in a variety of methods including by way of exam-
pie, but not limited thereto, intravenously, orally, sup-
pository, inhalation, and the like. Furthermore, it is 
generally felt that the compositions as claimed either 35 
specifically possess antiarrhythmic activity or generally 
are broadly biologically active or the respective compo-
sitions are intermediaries to antiarrhythmic and biologi-
cally active species that are released or created in situ as 
the result of the administration of the drug. 40 
Having thus described and exemplified the preferred 
embodiments with a certain degree of particularity, it is 
to be understood that the invention is not to be limited 
to the embodiments set forth herein for purposes of 
45 exemplification, but is to be limited only by the scope of 
the attached claims, including a full range of equivalents 
to which each element thereof is entitled. 
We claim: 
1. An antiarrhythmic compound selected from the 
50 
group consisting of: 
(a) 
55 
where R is 
60 
65 
and X is either H, Cl or OCH3; 
12 
(b) 
where R is 
and Xis either H, Cl, or OCH3 and Y is Cl, Br, or 
Cl04; 
(c) 
where R is 
and X is either H, Cl or OCH3; 
(d) 
where R is 
and X is either H, Cl or OCH3 and Y is Cl, Br, or 
Cl04; 
(e) 
where R is 
13 
4,58t361 
and X is either H. Cl or OCH3 and Ar is 
(f) 
where R is 
-cu,-©-x~ -cH,-CH,-©-x 
and X is either H. Cl or OCH3 and Ar is 
and Y is Cl, Br or Cl04. 
14 
5 
and X is either H, Cl or OCH3 and Y is Cl, Br, or Cl04. 
4. An antiarrhythmic compound of claim 1 having 
10 the formula: 
15 
20 where R is 
25 
and Xis either H, Cl or OHC3. 
5. An antiarrhythmic compound of claim 1 having 
30 the formula: 
35 
2. An antiarrhythmic compound of claim 1 having 40 where R is 
the formula: 
where R is 
and X is either H, Cl or OCH3. 
3. An antiarrhythmic compound of claim 1 having 
the formula: 
where R is 
45 
and X is either H, Cl, or OCH3 and Y is Cl, Br, or Cl04. 
6. An antiarrhythmic compound of claim 1 having 
SO the formula: 
55 
60 where R is 
65 




7. An antiarrhythmic compound of claim 1 having 
the formula: 
where R is 
-cu,-@-x" -cu,-cu,-@-x 
and X is either H, Cl or OCH3 and Ar is 






8. An antiarrhythmic compound of claim 2, 4 or 6 35 
wherein R is 
9. An antiarrhythmic compound of claim 3, 5 or 7 
wherein R is 




10. An antiarrhythmic process comprising the step of 
administering a dosage an antiarrhythmically effective 55 





/ """' S CH2 N-R "" / / 65 CH2-CH-CH2 
where R is 
and X is either H, Cl, or OCH3; 
(b) 
where R is 




/ "" "' S C=O N-R "" / / CH2-CH-CH2 
where R is 
and X is either H, Cl, or OCH3; 
(d) 
CH2-CH--CH2 
/ "" "" /R s c=o +N , y-
"" / / "H CH2-CH--CH2 
where R is 





where R is 
and X is either H, Cl or OCH3 and Ar is 
and 
(f) 
where R is 
-CII,-©-X m -CH,-CII,-©-X 





12. An antiarrhythrnic process of claim 10 wherein 
the compound has the formula: 
where R is 
and X is either H, Cl or OCH3 and Y is Cl, Br, or Cl04. 
20 13. An antiarrhythrnic process of claim 10 wherein 
the compound has the formula: 
30 where R is 
35 
and X is either H, Cl or OCH3. 
14. An antiarrhythmic process of claim 10 wherein 
40 the compound has the formula: 
45 
where R is and Y is Cl, Br or Cl04. 
11. An antiarrhythrnic process of claim 10 wherein 50 
the compound has the formula: 
55 
where R is 60 
65 
and X is either H, Cl or OCH3. 
and X is either H, Cl or OCH3 and Y is Cl, Br, or Cl04. 
15. An antiarrhythrnic process of claim 10 wherein 
the compound has the formula: 





and X is either H, Cl or OCH3 and Ar is 
10 
16. An antiarrhythmic process of claim 10 wherein 15 
the compound has the formula: 
where R is 
and X is either H, Cl or OCH3 and Ar is 
and Y is Cl, Br and Cl04. 
17. An antiarrhythmic process of claim 12 wherein 
said compound is 7-Benzyl-3-thia-7-azabicyclo[3.3.l-






18. An antiarrhythmic process of claim 17 wherein 45 
said doage rate is from about 6 mg/kg to about 18 
mg/kg. 
19. A 3-thia-7-azabicyclo[3.3.l]nonane compound 
selected from the group consisting of: 
(a) 
where R is 
-ca,-@-x" -ca,-cH,-@-x 







where R is 
and X is either H, Cl or OCH3 and Y is Cl, Br, or 
Cl04; 
(c) 
where R is 
and X is either H, Cl or OCH3; 
(d) 
where R is 
and Xis either H, Cl or OCH3 and Y is Cl, Br, or 
Cl04; 
(e) 




and X is either H, Cl or OCH3 and Ar is 
and 
(f) 
where R is 
-cu,-@-xoc -rn,-cu,-@-x 
and X is either H, Cl or OCH3 and Ar is 
and Y is Cl, Br, or Cl04. 
20. A compound of the formula: 
where R is 
and X is either H, Cl or OCH3. 
21. A compound of the formula: 






and X is either H, Cl or OCH3 and Y is Cl, Br, or Cl04. 
22. A compound of the formula: 
where R is 
-cu,-@-x o, -cu,-cu,-©-x 
25 and X is either H, Cl or OCH3. 
23. A compound of the formula: 
30 





and X is either H, Cl or OCH3 and Y is Cl, Br, or Cl04. 
24. A compound of the formula: 
where R is 
60 and X is either H, Cl or OCH3 and Ar is 
65 
25. A compound of the formula: 
23 
where R is 




and Y is Cl, Br or Cl04. 
26. The compound 7-benzyl-3-thia-7-azabicy-
clo[3.3.1 ]nonan-9-one. 
10 27. The compound 7-benzyl-3-thia-7-azabicy-
clo[3.3.l]nonane. 
28. The compound 9-hydroxyl-9-phenyl-7-benzyl-3-
thia-7-azabicyclo[3.3. l]nonane. 
29. The amine acid salt of the compound of claims 23, 
15 24 or 25 wherein said acid is selected from the group 
consisting of HCl, HBr, and HCl04. 
* • * • * 
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